Holen Sie sich die Stockscreener-App
88.24
0.35%
-0.31
Handel nachbörslich:
88.24
Schlusskurs vom Vortag:
$88.55
Offen:
$89.97
24-Stunden-Volumen:
1.11M
Relative Volume:
0.93
Marktkapitalisierung:
$4.30B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-192.89M
KGV:
-22.64
EPS:
-3.8976
Netto-Cashflow:
$-172.97M
1W Leistung:
+0.93%
1M Leistung:
-35.91%
6M Leistung:
-13.64%
1J Leistung:
+628.65%
1-Tages-Spanne:
$86.53
$90.61
1-Wochen-Bereich:
$85.54
$95.97
52-Wochen-Spanne:
$11.28
$151.02
Celcuity Inc Stock (CELC) Company Profile
Firmenname
Celcuity Inc
Sektor
Branche
Telefon
763-392-0767
Adresse
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
88.24 | 4.32B | 0 | -192.89M | -172.97M | -3.8976 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | Citizens | Mkt Outperform |
| 2025-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | Eingeleitet | Guggenheim | Buy |
| 2025-07-01 | Fortgesetzt | Stifel | Buy |
| 2024-07-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-02-22 | Eingeleitet | Stifel | Buy |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-09-07 | Eingeleitet | Jefferies | Buy |
| 2021-07-29 | Eingeleitet | Cowen | Outperform |
| 2021-07-27 | Eingeleitet | Needham | Buy |
| 2021-01-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-11 | Fortgesetzt | Craig Hallum | Buy |
| 2018-11-20 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Celcuity Inc Aktie (CELC) Neueste Nachrichten
Trading the Move, Not the Narrative: (CELC) Edition - Stock Traders Daily
CELC News | CELCUITY INC (NASDAQ:CELC) - ChartMill
CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data - Stocktwits
Guggenheim Initiates Coverage of Celcuity (CELC) with Buy Recommendation - MSN
CELC stock records worst day ever after late-stage breast cancer trial results — what’s driving the selloff? - MSN
ACT CAPITAL MANAGEMENT, LLC's Celcuity Inc(CELC) Holding History - GuruFocus
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff? - Stocktwits
Celcuity raises $500M in upsized 0.25% convertible notes sale - MSN
TD Asset Management Inc Has $9.73 Million Stake in Celcuity, Inc. $CELC - MarketBeat
CELC6416934 Bond Coupon Analysis — Rate & Payments - TradingView
Celcuity shares fall despite strong phase 3 breast cancer trial data (CELC) - MSN
Celcuity Refinances Debt with New Convertible Notes Offering - TipRanks
Celcuity Raises $575 Million in 0.25% Convertible Notes Due 2032; Net Proceeds $557 Million - TradingView
Geode Capital Management LLC Purchases 64,213 Shares of Celcuity, Inc. $CELC - MarketBeat
BNP Paribas Financial Markets Sells 36,648 Shares of Celcuity, Inc. $CELC - MarketBeat
CELC6416934 Bond Price and Chart — FINRA:CELC6416934 - TradingView
Preferred dividends of Celcuity Inc. – HAM:7VR - TradingView
Does Celcuity’s (CELC) Low‑Coupon Convertibles Hint at Strategic Caution or Commercial Ambition? - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
CELC6416934 Bond Analysis — Key Metrics - TradingView
Cash from investing activities of Celcuity Inc. – HAM:7VR - TradingView
Operating expenses (excl. COGS) of Celcuity Inc. – HAM:7VR - TradingView
After tax other income/expense of Celcuity Inc. – XETR:7VR - TradingView
Celcuity Inc. Cash Flow – LSX:A2JAAX - TradingView
ETFs Investing in Celcuity Inc. Stocks - TradingView
Non-operating income (total) of Celcuity Inc. – DUS:7VR - TradingView
Long term debt to total assets ratio of Celcuity Inc. – DUS:7VR - TradingView
Asset turnover of Celcuity Inc. – DUS:7VR - TradingView
Long term debt to total assets ratio of Celcuity Inc. – LS:A2JAAX - TradingView
Price to book ratio of Celcuity Inc. – DUS:7VR - TradingView
A2JAAX Stock Price and Chart — LS:A2JAAX - TradingView
Celcuity Inc. Balance Sheet – DUS:7VR - TradingView
Celcuity Inc. Statistics – DUS:7VR - TradingView
Celcuity Inc. Financial Statements – DUS:7VR - TradingView
Net income of Celcuity Inc. – DUS:7VR - TradingView
How Celcuity CEO Brian Sullivan Is Framing Cancer Drug Development Around Hope for Patients - SurvivorNet
Celcuity Inc. Financial Statements – LS:A2JAAX - TradingView
HC Wainwright Has Negative Estimate for Celcuity Q3 Earnings - MarketBeat
Celcuity falls after detailed late-stage trial data for breast cancer drug - MSN
Celcuity Expands VIKTORIA-2 Trial As Shares Trade Below Targets - Sahm
Celcuity director Richard Buller sells $1.26 million in stock - Investing.com
Celcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and Gedatolisib EfficacySlideshow (NASDAQ:CELC) 2026-06-04 - Seeking Alpha
Celcuity (CELC) Weighs Dilution Against Drug Development After $500 Million Convertible Note Offering - Yahoo Finance
Celcuity (NASDAQ:CELC) Sees Strong Trading VolumeShould You Buy? - MarketBeat
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $145 to $171 - Moomoo
Celcuity (CELC) Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients - Insider Monkey
H.C. Wainwright cuts Celcuity stock price target on revised penetration estimates - Investing.com UK
Wells Fargo cuts Celcuity stock price target on modest trial data - Investing.com UK
Finanzdaten der Celcuity Inc-Aktie (CELC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.40%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):